Abstract
Colorectal cancer (CRC), one of the most common cancers, is associated with significant morbidity, mortality, and medical costs. Treatment options in metastatic CRC are largely palliative, and aim to provide symptom relief, improve health-related quality of life, and prolong survival. Chemotherapy is the mainstay of treatment for metastatic disease. Fluorouracil/leucovorin with or without oxaliplatin or irinotecan is the most widely used regimen. These agents are administered intravenously (by bolus or infusion), thereby causing significant inconvenience to patients.
Capecitabine (Xeloda®), an oral fluoropyrimidine, is currently recommended as single-agent first-line treatment in patients with metastatic CRC in whom fluoropyrimidine monotherapy is the preferred option. As first-line monotherapy, capecitabine is as least as clinically effective as bolus fluorouracil/leucovorin in terms of time to disease progression, time to treatment failure, and overall survival, but achieves significantly higher response rates and has the added advantage of oral administration. In addition, capecitabine has improved tolerability with a significantly lower incidence of diarrhea, stomatitis, nausea, and alopecia than fluorouracil/leucovorin. The lower incidence of grade 3 or 4 neutropenia with capecitabine results in significantly less neutropenic fever/sepsis and, consequently, fewer hospitalizations. The significantly higher incidence of hand-and-foot syndrome with capecitabine rarely necessitates hospitalization.
Measures of resource utilization found patients treated with capecitabine had fewer hospital visits for drug administration, fewer days in hospital for management of treatment-related adverse events, and required less expensive drug therapy for the management of adverse events than fluorouracil/leucovorin recipients. In cost-minimization studies in various countries, these benefits translated into cost savings with capecitabine relative to fluorouracil/leucovorin.
Clinical trials have shown combination therapy with capecitabine and either irinotecan or oxaliplatin to be effective and well tolerated. Capecitabine appears to be an acceptable alternative to fluorouracil/leucovorin in combination therapy. Moreover, one economic analysis predicted that capecitabine plus oxaliplatin will result in cost savings compared with fluorouracil/leucovorin plus oxaliplatin.
In conclusion, oral capecitabine offers an effective, but more convenient, alternative to bolus fluorouracil/leucovorin in the first-line treatment of patients with metastatic CRC. The improved tolerability and cost savings of capecitabine relative to fluorouracil/leucovorin support the use of capecitabine when treatment with fluoropyrimidine therapy alone is the preferred option. Results of further phase III trials of capectabine plus either irinotecan or oxaliplatin are eagerly awaited to determine if replacing fluorouracil/leucovorin with capecitabine in combination therapy will result in further improvements in convenience, tolerability, and, ultimately, cost savings for patients and payors in the metastatic CRC setting.
Similar content being viewed by others
Notes
The use of trade names is for product identification purposes only and does not imply endorsement.
References
National Cancer Institute. Colorectal cancer (PDQ): screening [online]. Available from URL: http://www.cancer.gov [Accessed 2004 Dec 7]
American Cancer Society. Cancer reference information: colorectal cancer [online]. Available from URL: http://www.cancer.org [Accessed 2005 Jan 19]
National Comprehensive Cancer Network. NCCN practice guidelines in oncology — v.1.2005: colon cancer [online]. Available from URL: http://nccn.org [Accessed 2004 Dec 7]
National Institute for Clinical Excellence. Guidance on cancer services: improving outcomes in colorectal cancers; manual update. London: National Institute for Clinical Excellence, 2004 May
Antimetabolites. In: Mehta DK, editor. British national formulary. 48th ed. London: The British Medical Association and the Royal Pharmaceutical Society of Great Britain, 2004: 428–31
Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 2000 Sep 2; 321(7260): 531–5
McGavin JK, Goa KL. Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer. Drugs 2001; 61(15): 2309–26
National Cancer Institute. Colon cancer (PDQ): treatment [online]. Available from URL: http://www.cancer.gov [Accessed 2004 Nov 17]
Dunn J, Lynch B, Aitken J, et al. Quality of life and colorectal cancer: a review. Aust N Z J Public Health 2003; 27(1): 41–53
Efficace F, Bottomley A, Vanvoorden V, et al. Methodological issues in assessing health-related quality of life of colorectal cancer patients in randomised controlled trials. Eur J Cancer 2004 Jan; 40(2): 187–97
Maisey NR, Norman A, Watson M, et al. Baseline quality of life predicts survival in patients with advanced colorectal cancer. Eur J Cancer 2002 Jul; 38(10): 1351–7
Brown ML, Lipscomb J, Snyder C. The burden of illness of cancer: economic cost and quality of life. Annu Rev Public Health 2001; 22: 91–113
Redaelli A, Cranor CW, Okano GJ, et al. Screening, prevention and socioeconomic costs associated with the treatment of colorectal cancer. Pharmacoeconomics 2003; 21(17): 1213–38
Geddes M, Carli S, Ercolanelli M, et al. Colorectal, lung, and breast cancer care during the three years following the diagnosis: a population-based study. Tumori 1996; 82(3): 210–4
Eaddy M, Bramley T, Kozma C, et al. Cost of colorectal cancer in the South Carolina Medicaid (SCM) population [abstract no. 1633]. Proc Am Soc Clin Oncol 1999 May 15; 18: 423a
Neymark N, Adriaenssen I. The costs of managing patients with advanced colorectal cancer in 10 different European centres. Eur J Cancer A 1999 Dec; 35: 1789–95
National Institute for Clinical Excellence. Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer. London: National Institute for Clinical Excellence, 2003 May. Technology appraisal no. 61
National Institute for Clinical Excellence. Irinotecan, oxaliplatin & raltitrexed for advanced colorectal cancer: full guidance. London: National Institute for Clinical Excellence, 2002 Mar. Technology appraisal guidance no. 33
Arbuck SG. Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer. Cancer 1989; 63: 1036–44
Petrelli N, Douglass HO, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial [published erratum in: J Clin Oncol 1990 Jan; 8 (1): 185]. J Clin Oncol 1989 Oct; 7(10): 1419–26.
Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group. N Engl J Med 2000 Sep 28; 343(13): 905–14
Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000 Mar 25; 355(9209): 1041–7
Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000 Jan; 18(1): 136–47
de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18(16): 2938–47
Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004 Jan 1; 22(1): 23–30
Genentech, Inc.. Avastin (bevacizumab) prescribing information. South San Francisco ((CA)): Genentech, Inc., 2004 Apr
Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003 Jan 1; 21(1): 60–5
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004 Jun 3; 350(23): 2335–42
Carmichael J, Popiela T, Radstone D, et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002 Sep 1; 20(17): 3617–27
Douillard JY, Hoff PM, Skillings JR, et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002 Sep 1; 20(17): 3605–16
Roche Pharmaceuticals. Xeloda (capecitabine) tablets: complete product information [online]. Available from URL: http://www.xeloda.com [Accessed 2004 Dec 7]
European Medicines Agency. Xeloda: summary of product characteristics [online]. Available from URL: http://www.emea.eu.int [Accessed 2005 Jan 26]
Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001 Apr; 19(8): 2282–92
Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001 Nov 1; 19: 4097–106
Fluorouracil. In: McEvoy GK, editor. AHFS drug information 2004. Bethesda ((MD)): American Society of Health-System Pharmacists, 2004: 1000–5
Pfizer. Camptosar (irinotecan hydrochloride injection): prescribing information. New York: Pfizer, 2004 Jul
Sanofi-Synthelabo Inc.. Eloxatin (oxaliplatin for injection): prescribing information. New York: Sanofi-Synthelabo Inc, 2004 Jun
Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist 2002; 7(4): 288–323
Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998 Jul; 34(8): 1274–81
Ishikawa T, Utoh M, Sawada N, et al. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 1998 Apr 1; 55(7): 1091–7
Twelves C. Capecitabine as first-line treatment in colorectal cancer: pooled data from two large, phase III trials. Xeloda Colorectal Cancer Group. Eur J Cancer 2002 Feb; 38 Suppl. 2: 15–20
Borner MM, Dietrich D, Stupp R, et al. Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 2002 Apr 1; 20: 1759–66
Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004 Jun 1; 22(11): 2084–91
Scheithauer W, Kornek GV, Raderer M, et al. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003 Apr 1; 21: 1307–12
Shields AF, Zalupski MM, Marshall JL, et al. Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial. Cancer 2004 Feb 1; 100(3): 531–7
Bajetta E, Di Bartolomeo M, Mariani L, et al. Randomized multicenter phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 2004 Jan 15; 100(2): 279–87
Burris HA, Kalman L, Bertoli L, et al. Continuous flat-dose capecitabine plus weekly irinotecan: an alternative first-line treatment for metastatic colorectal cancer [abstract no. 229]. 2004 Gastrointestinal Cancers Symposium; 2004 Jan 22–24; San Francisco
Muñoz A, Salud A, Alonso V, et al. Final analysis of irinotecan (CPT-11) and capecitabine (X) as first-line treatment of locally advanced (LA) or metastatic colorectal cancer (MCRC) [abstract no. 3610]. J Clin Oncol 2004; 22(14 Suppl.): 272s
Patt YZ, Liebmann J, Diamandidis D, et al. Capecitabine (Xeloda) plus irinotecan (XELIRI) as first-line chemotherapy for metastatic colorectal cancer (MCRC): final findings from a phase II trial [abstract no. 3602]. J Clin Oncol 2004; 22(14 Suppl.): 270s. Plus poster presented at the 2004 American Society of Clinical Oncology Annual Meeting; 2004 Jan 22–24; San Francisco
Grothey A, Jordan K, Kellner O, et al. Capecitabine plus irinotecan (CAPIRI) vs capecitabine plus oxaliplatin (CAPOX) as first-line therapy of advanced colorectal cancer (ACRC): updated results of a randomized phase II trial [abstract no. 295]. Eur J Cancer Suppl 2003; 1(5 Suppl.): S90
Grothey A, Jordan K, Kellner O, et al. Capecitabine/irinotecan and capecitabine/oxaliplatin are active second-line protocols in patients with advanced colorectal cancer after failure of first-line combination therapy: results of a randomized phase II study [abstract no. 3534]. J Clin Oncol 2004; 22(14 Suppl.): 253s
Arkenau HT, Kubicka S, Grall R, et al. Phase III trial of infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of advanced colorectal carcinoma (ACRC): results of an interim efficacy and safety analysis [abstract no. 272PD]. Ann Oncol 2004; 15 Suppl. 3: iii72
Twelves C, Boyer M, Findlay M, et al. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer 2001 Mar; 37: 597–604
Jansman FGA, Postma MJ, van Hartskamp D, et al. Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands. Clin Ther 2004 Apr; 26(4): 579–89
Omnes LF, Woronoff Lemsi MC, Foutel V. Pharmaco-economic assessment of capecitabine oral chemotherapy versus FuFol Mayo Clinic chemotherapy in the treatment of colorectal cancer [abstract no. PCN8]. Value Health 2003 Nov–Dec 31; 6(6): 733–4
Ward S, Kaltenthaler E, Cowan J, et al. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2003; 7(32): 1–93
Wiklund TA, Pekurinen M. Pharmacoeconomic comparison of capecitabine vs. intravenous 5-FU/leucovorin (Mayo protocol) in colorectal cancer in Finland [abstract no. 2134]. Proc Am Soc Clin Oncol 2003; 22: 530
Baran RW, Dupere W, Taylor K, et al. Clinical and economic outcomes associated with metastatic breast cancer (MBC) and colorectal cancer (CRC) in managed care populations: capecitabine versus comparator therapies [abstract]. J Manage Care Pharm 2002 Mar–Apr; 8(2): 109
Chu E, Diaz-Rubio E, Marshall J, et al. Economic analysis of potential medical cost savings of XELOX (capecitabine and oxaliplatin combination) in metastatic colorectal cancer [abstract no. 1080]. Proc Am Soc Clin Oncol 2003; 22: 269
Beato C, Federico M, Cabral S, et al. Capecitabine (X) improves quality of life (QoL) in patients (pts) with metastatic colorectal cancer (MCRC) [abstract no. 332P]. Ann Oncol 2004; 15 Suppl. 3: iii89
Schwarz RE, Coit DG, Groeger JS. Transcutaneously tunneled central venous lines in cancer patients: an analysis of device-related morbidity factors based on prospective data collection. Ann Surg Oncol 2000; 7(6): 441–9
Viale PH. Complications associated with implantable vascular access devices in the patient with cancer. J Infus Nurs 2003; 26(2): 97–102
Borner M, Scheithauer W, Twelves C, et al. Answering patients’ needs: oral alternatives to intravenous therapy. Oncologist 2001; 6 Suppl. 4: 12–6
Author information
Authors and Affiliations
Corresponding author
Additional information
Various sections of the manuscript reviewed by: M.M. Borner, Institute of Medical Oncology, Inselspital, Bern, Switzerland; K. Bujko, Department of Radiotherapy, The Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland; T. Conroy, Department of Medical Oncology, Centre Alexis Vautrin, Nancy, France; A.F. Grothey, Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA; F.G.A. Jansman, Department of Clinical Pharmacy, Isala Klinieken, Zwolle, The Netherlands; M. Malet-Martino, Groupe de RMN Biomedicale, Laboratoire des IMRCP, Universite Paul Sabatier, Toulouse, France; J.J. McKendrick, Department of Hematology and Medical Oncology, Box Hill Hospital, Melbourne, Australia; W. Scheithauer, Department of Internal Medicine, University Medical School, Vienna, Austria; P. Schöffski, Department of Clinical Oncology, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium.
Data Selection
Sources: Medical literature published in any language since 1980 on drug-name, identified using Medline, supplemented by AdisBase (a proprietary database of Adis International). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug.
Search strategy: Medline search terms were ‘colorectal cancer’ or ‘colorectal neoplasms’ and (‘guidelines’ or ‘decision-making’ or ‘health-policy’ or ‘managed-care-programmes’ or ‘epidemiology’ or ‘outcome-assessment-health-care’ or ‘clinical-protocols’ or ‘guideline in pt’ or ‘polic* in ti’ or ‘expert panel’ or ‘utilization review’ or ‘algorithms’ or ‘disease management’ or ‘quality of life’), or ‘capecitabine’ and ‘review in pt’. AdisBase search terms were ‘colorectal cancer’ and (‘guideline’ or ‘guideline-utilisation’ or ‘practice-guideline’ or ‘disease-management-programmes’ or ‘treatment-algorithms’ or ‘reviews-on-treatment’ or ‘drug-evaluations’ or ‘epidemiology’ or ‘cost-of-illness’ or ‘pathogenesis’), or ‘capecitabine’ and (‘review’ or ‘clinical-study’). Searches were last updated 2005 February 14.
Selection: Studies in patients with colorectal cancer who received capecitabine. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic, pharmacokinetic, pharmacoeconomic and epidemiological data are also included.
Index terms: Capecitabine, colorectal cancer, disease management, review on treatment.
Rights and permissions
About this article
Cite this article
Wiseman, L.R., Lyseng-Williamson, K.A. Management of Metastatic Colorectal Cancer. Dis-Manage-Health-Outcomes 13, 137–149 (2005). https://doi.org/10.2165/00115677-200513020-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00115677-200513020-00007